Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030
안과 치료제 시장 규모는 2025년 195억 2,000만 달러에서 2030년에는 262억 8,000만 달러로 성장하며, 예측 기간 중 CAGR은 6.1%를 기록할 것으로 예측됩니다.
안과 치료제 시장의 성장은 주로 노화와 관련된 안과 질환의 유병률 증가와 이러한 증상을 치료할 수 있는 몇 가지 주요 치료제의 가용성에 의해 주도되고 있습니다. 또한 다양한 치료법에 걸친 강력한 신약 파이프라인이 이러한 성장에 기여하고 있습니다. 아시아태평양, 라틴아메리카, 중동 및 아프리카 등 신흥 경제권에서의 지역적 확장 기회도 시장 개발을 지원하고 있습니다.
| 조사 범위 |
| 조사 대상연도 |
2024-2030년 |
| 기준연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 검토 단위 |
금액(10억 달러) |
| 부문 |
분자별, 모달리티별, 적응증별, 투여 경로별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
망막질환 치료의 미충족 수요, 약물전달의 발전, 최근 제품 승인으로 인해 단클론 항체(mAbs) 및 융합 단백질이 가장 높은 성장률을 보일 것으로 예측됩니다. 바이오시밀러의 도입과 KSI-301과 같은 신제품의 등장으로 경쟁이 치열해지고 비용이 절감될 것으로 예상되며, Regeneron과 Roche를 비롯한 주요 시장 진출기업은 성장에 필수적인 반면, 지불자의 수용성 및 기술 혁신과 같은 요인은 시장 역학에 큰 영향을 미칠 것으로 예측됩니다. 영향을 미칩니다.
또한 신흥 시장에서는 이러한 치료법의 채택이 증가하고 있으며, 특히 바이오시밀러의 경우 더 나은 접근성과 저렴한 가격의 혜택을 누리고 있습니다. 적은 투여 횟수는 이러한 치료법의 비용 효율성을 더욱 높여줍니다. 서방형 임플란트 및 유전자 치료와 같은 기술 혁신도 이 분야의 성장에 기여하고 있습니다. 전반적으로 바이오시밀러는 공급을 확대하고 치료량을 증가시키고 있습니다.
미국은 2025-2035년까지 안과용 의약품 세계 시장에서 가장 높은 CAGR을 보일 것으로 예측됩니다. 이러한 급격한 성장의 주요 요인은 인구의 고령화와 연령 관련 황반변성(AMD) 및 당뇨병성 황반부종(DME)의 높은 유병률에 기인합니다. 또한 미충족 의료 수요, Syfovre 및 Izervay와 같은 최근 의약품 승인, 유망한 유전자 및 세포치료제 파이프라인도 있습니다. 미국은 또한 강력한 R&D 생태계, 효율적인 FDA 승인 프로세스, 활발한 투자의 혜택을 누리고 있습니다. 또한 유리한 상환 환경, 메디케어 적용, 고가의 치료법 채택에 대한 의지가 이러한 성장에 크게 기여하고 있습니다.
세계의 안과 치료제 시장에 대해 조사했으며, 분자별, 모달리티별, 적응증별, 투여 경로별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 개요
제4장 주요 인사이트
제5장 시장 개요
- 서론
- 시장 역학
- 기술 분석
- 고객 비즈니스에 영향을 미치는 동향/혼란
- 가격 분석
- 밸류체인 분석
- 에코시스템 분석
- 특허 분석
- 규제 분석
- Porter's Five Forces 분석
- 2025-2026년의 주요 컨퍼런스와 이벤트
- 상환 시나리오
- 주요 이해관계자와 구입 기준
- 투자와 자금조달 시나리오
- 파이프라인 분석
- 인공지능이 안과의 약품 시장에 미치는 영향
- 2025년 미국 관세가 안과의 약품 시장에 미치는 영향
제6장 안과 치료제 시장(분자별)
- 서론
- AFLIBERCEPT
- FARICIMAB
- RANIBIZUMAB
- 기타
제7장 안과 치료제 시장(모달리티별)
- 서론
- 모노클로널 항체와 융합단백질
- 저분자
- 기타
제8장 안과 치료제 시장(적응증별)
- 서론
- 노인황반변성
- 당뇨망막병증(DR)
- 당뇨병성 황반부종(DME)
- 기타
제9장 안과 치료제 시장(투여 경로별)
제10장 안과 치료제 시장(최종사용자별)
제11장 안과 치료제 시장(지역별)
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동
- 아프리카
- 헬스케어에 대한 주목의 증가가 시장의 성장을 촉진
- 아프리카의 거시경제 전망
제12장 경쟁 구도
- 서론
- 주요 참여 기업의 전략/강점
- 매출 분석, 2022-2024년
- 시장 점유율 분석, 2024년
- 기업 평가 상한 : 주요 참여 기업, 2024년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
- 기업 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제13장 기업 개요
- 주요 참여 기업
- REGENERON PHARMACEUTICALS INC.
- F. HOFFMANN-LA ROCHE LTD.
- BAYER AG
- NOVARTIS AG
- ABBVIE
- APELLIS PHARMACEUTICALS
- BIOGEN
- BAUSCH+LOMB
- ASTELLAS PHARMA INC.
- FORMYCON AG
- BIOCON
- SANDOZ GROUP AG
- SANTEN PHARMACEUTICAL CO., LTD.
- INNOVENT
- OUTLOOK THERAPEUTICS, INC.
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 기타 기업(파이프라인 기업)
- OCULAR THERAPEUTIX, INC.
- OPTHEA LIMITED
- KODIAK SCIENCES INC.
- EYEPOINT PHARMACEUTICALS, INC.
- ALVOTECH
- CLEARSIDE BIOMEDICAL
- SHANGHAI HENLIUS BIOTECH, INC.
- ADVERUM BIOTECHNOLOGIES, INC.
- REMEGEN
- SPARINGVISION
제14장 부록
KSA
The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market's development.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Molecule, Modality, Indication, Route of Administration, End user |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period.
Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics.
In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume.
The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030.
The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others.
Research Coverage:
This research report categorizes the ophthalmology drugs market by molecule (aflibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Objectives of secondary research
- 2.1.1.2 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
- 2.1.2.2 Key objectives of primary research
- 2.2 MARKET ESTIMATION METHODOLOGY
- 2.2.1 GLOBAL MARKET ESTIMATION
- 2.2.1.1 Product revenue analysis (bottom-up approach)
- 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc.
- 2.2.1.3 MnM repository analysis
- 2.2.1.4 Primary interviews
- 2.2.2 INSIGHTS OF PRIMARY EXPERTS
- 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW
- 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
- 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024
- 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Aging population and growing prevalence of vision disorders
- 5.2.1.2 Strong drug pipeline and growing innovation efforts
- 5.2.1.3 Increasing investments and strategic collaborations
- 5.2.1.4 Improved reimbursement policies
- 5.2.2 RESTRAINTS
- 5.2.2.1 Off-label drug use for various indications
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Shifting focus on new drug modalities
- 5.2.3.2 Expansion into emerging markets
- 5.2.3.3 High unmet needs
- 5.2.4 CHALLENGES
- 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment
- 5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
- 5.3.1.1 Hybridoma technology
- 5.3.1.2 Recombinant DNA technology
- 5.3.1.3 Antibody engineering
- 5.3.1.4 Gene therapy
- 5.3.1.5 Nanoformulations
- 5.3.2 ADJACENT TECHNOLOGIES
- 5.3.2.1 Optogenetic technology
- 5.3.2.2 Drug-release technologies
- 5.3.2.3 Ocular implant technologies
- 5.3.3 COMPLEMENTARY TECHNOLOGIES
- 5.3.3.1 3D printing and bioprinting
- 5.3.3.2 Ocular imaging technologies
- 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.5 PRICING ANALYSIS
- 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
- 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
- 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
- 5.6 VALUE CHAIN ANALYSIS
- 5.7 ECOSYSTEM ANALYSIS
- 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
- 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
- 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
- 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
- 5.8 PATENT ANALYSIS
- 5.9 REGULATORY ANALYSIS
- 5.9.1 REGULATORY LANDSCAPE
- 5.9.1.1 US
- 5.9.1.2 Europe
- 5.9.1.3 Emerging markets
- 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10 PORTER'S FIVE FORCES ANALYSIS
- 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
- 5.10.2 BARGAINING POWER OF SUPPLIERS
- 5.10.3 BARGAINING POWER OF BUYERS
- 5.10.4 THREAT OF SUBSTITUTES
- 5.10.5 THREAT OF NEW ENTRANTS
- 5.11 KEY CONFERENCES & EVENTS, 2025-2026
- 5.12 REIMBURSEMENT SCENARIO
- 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
- 5.14 INVESTMENT & FUNDING SCENARIO
- 5.15 PIPELINE ANALYSIS
- 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
- 5.16.1 CHALLENGES IN DRUG DISCOVERY
- 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
- 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
- 5.17.1 KEY TARIFF RATES
- 5.17.2 PRICE IMPACT ANALYSIS
- 5.17.3 KEY IMPACT ON VARIOUS REGIONS
- 5.17.3.1 US
- 5.17.3.2 Europe
- 5.17.3.3 APAC
- 5.17.4 MANUFACTURING INDUSTRY IMPACT
- 5.17.4.1 Ophthalmology drug manufacturers
6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
- 6.1 INTRODUCTION
- 6.2 AFLIBERCEPT
- 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
- 6.3 FARICIMAB
- 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
- 6.4 RANIBIZUMAB
- 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
- 6.5 OTHER MOLECULES
7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY
- 7.1 INTRODUCTION
- 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS
- 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
- 7.3 SMALL MOLECULES
- 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
- 7.4 OTHER MODALITIES
8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION
- 8.1 INTRODUCTION
- 8.2 AGE-RELATED MACULAR DEGENERATION
- 8.2.1 WET AGE-RELATED MACULAR DEGENERATION
- 8.2.1.1 Increasing demand for effective therapies to drive market
- 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION
- 8.2.2.1 Large market opportunity for innovation to drive growth
- 8.3 DIABETIC RETINOPATHY (DR)
- 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
- 8.4 DIABETIC MACULAR EDEMA (DME)
- 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
- 8.5 OTHER INDICATIONS
9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION
- 9.1 INTRODUCTION
- 9.2 INTRAVITREAL
- 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
- 9.3 TOPICAL
- 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
- 9.4 OTHER ROUTES OF ADMINISTRATION
10 OPHTHALMOLOGY DRUGS MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 HOSPITALS
- 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
- 10.3 LONG-TERM CARE FACILITIES
- 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
- 10.4 SPECIALTY CENTERS
- 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH
11 OPHTHALMOLOGY DRUGS MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
- 11.2.2.1 Rising investments in healthcare research and development to support growth
- 11.2.3 CANADA
- 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth
- 11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
- 11.3.2.1 Rising focus on clinical research to drive market
- 11.3.3 UK
- 11.3.3.1 Ongoing advancements in technology to drive market growth
- 11.3.4 FRANCE
- 11.3.4.1 Growing investments and government support to drive market growth
- 11.3.5 ITALY
- 11.3.5.1 Growing investments and research to support market
- 11.3.6 SPAIN
- 11.3.6.1 Growing geriatric population to drive market growth
- 11.3.7 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 CHINA
- 11.4.2.1 Large diabetic population to boost market
- 11.4.3 JAPAN
- 11.4.3.1 Growing aging population to intensify demand for effective treatments
- 11.4.4 INDIA
- 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market
- 11.4.5 AUSTRALIA
- 11.4.5.1 Strong biopharmaceutical sector to drive market growth
- 11.4.6 SOUTH KOREA
- 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments
- 11.5.3 MEXICO
- 11.5.3.1 Growing research initiatives and innovations to support market growth
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 INTRODUCTION
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
- 12.3 REVENUE ANALYSIS, 2022-2024
- 12.4 MARKET SHARE ANALYSIS, 2024
- 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
- 12.5.1 STARS
- 12.5.2 EMERGING LEADERS
- 12.5.3 PERVASIVE PLAYERS
- 12.5.4 PARTICIPANTS
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 12.5.5.1 Company footprint
- 12.5.5.2 Region footprint
- 12.5.5.3 Molecule footprint
- 12.5.5.4 Modality footprint
- 12.5.5.5 Indication footprint
- 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 12.6.5.1 Detailed list of key startups/SMEs
- 12.6.5.2 Competitive benchmarking of startups/SMEs
- 12.7 COMPANY VALUATION & FINANCIAL METRICS
- 12.7.1 VALUATION OF KEY PLAYERS
- 12.7.2 FINANCIAL METRICS OF KEY PLAYERS
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT LAUNCHES & APPROVALS
- 12.9.2 DEALS
13 COMPANY PROFILES
- 13.1 KEY PLAYERS
- 13.1.1 REGENERON PHARMACEUTICALS INC.
- 13.1.1.1 Business overview
- 13.1.1.2 Products offered
- 13.1.1.3 Recent developments
- 13.1.1.3.1 Product approvals
- 13.1.1.4 MnM view
- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 F. HOFFMANN-LA ROCHE LTD.
- 13.1.2.1 Business overview
- 13.1.2.2 Products offered
- 13.1.2.3 Recent developments
- 13.1.2.3.1 Product launches & approvals
- 13.1.2.4 MnM view
- 13.1.2.4.1 Right to win
- 13.1.2.4.2 Strategic choices
- 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 BAYER AG
- 13.1.3.1 Business overview
- 13.1.3.2 Products offered
- 13.1.3.3 Recent developments
- 13.1.3.3.1 Product approvals
- 13.1.3.4 MnM view
- 13.1.3.4.1 Right to win
- 13.1.3.4.2 Strategic choices
- 13.1.3.4.3 Weaknesses & competitive threats
- 13.1.4 NOVARTIS AG
- 13.1.4.1 Business overview
- 13.1.4.2 Products offered
- 13.1.4.3 Recent developments
- 13.1.4.3.1 Product approvals
- 13.1.4.3.2 Deals
- 13.1.4.4 MnM view
- 13.1.4.4.1 Right to win
- 13.1.4.4.2 Strategic choices
- 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 ABBVIE
- 13.1.5.1 Business overview
- 13.1.5.2 Products offered
- 13.1.6 APELLIS PHARMACEUTICALS
- 13.1.6.1 Business overview
- 13.1.6.2 Products offered
- 13.1.6.3 Recent developments
- 13.1.6.3.1 Product approvals
- 13.1.6.3.2 Deals
- 13.1.7 BIOGEN
- 13.1.7.1 Business overview
- 13.1.7.2 Products offered
- 13.1.7.3 Recent developments
- 13.1.7.3.1 Product launches & approvals
- 13.1.8 BAUSCH + LOMB
- 13.1.8.1 Business overview
- 13.1.8.2 Products offered
- 13.1.8.3 Recent developments
- 13.1.8.3.1 Product launches & approvals
- 13.1.9 ASTELLAS PHARMA INC.
- 13.1.9.1 Business overview
- 13.1.9.2 Products offered
- 13.1.9.3 Recent developments
- 13.1.9.3.1 Product approvals
- 13.1.9.3.2 Deals
- 13.1.10 FORMYCON AG
- 13.1.10.1 Business overview
- 13.1.10.2 Products offered
- 13.1.10.3 Recent developments
- 13.1.10.3.1 Product launches & approvals
- 13.1.10.3.2 Deals
- 13.1.11 BIOCON
- 13.1.11.1 Business overview
- 13.1.11.2 Products offered
- 13.1.11.3 Recent developments
- 13.1.11.3.1 Product approvals
- 13.1.11.3.2 Deals
- 13.1.12 SANDOZ GROUP AG
- 13.1.12.1 Business overview
- 13.1.12.2 Products offered
- 13.1.12.3 Recent developments
- 13.1.12.3.1 Product approvals
- 13.1.12.3.2 Deals
- 13.1.13 SANTEN PHARMACEUTICAL CO., LTD.
- 13.1.13.1 Business overview
- 13.1.13.2 Products offered
- 13.1.13.3 Recent developments
- 13.1.13.3.1 Product launches
- 13.1.14 INNOVENT
- 13.1.14.1 Business overview
- 13.1.14.2 Products offered
- 13.1.14.3 Recent developments
- 13.1.14.3.1 Product approvals
- 13.1.15 OUTLOOK THERAPEUTICS, INC.
- 13.1.15.1 Business overview
- 13.1.15.2 Products offered
- 13.1.15.3 Recent developments
- 13.1.15.3.1 Product approvals
- 13.1.15.3.2 Deals
- 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
- 13.1.16.1 Business overview
- 13.1.16.2 Products offered
- 13.1.16.3 Recent developments
- 13.1.16.3.1 Product approvals
- 13.1.16.3.2 Deals
- 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
- 13.2.1 OCULAR THERAPEUTIX, INC.
- 13.2.2 OPTHEA LIMITED
- 13.2.3 KODIAK SCIENCES INC.
- 13.2.4 EYEPOINT PHARMACEUTICALS, INC.
- 13.2.5 ALVOTECH
- 13.2.6 CLEARSIDE BIOMEDICAL
- 13.2.7 SHANGHAI HENLIUS BIOTECH, INC.
- 13.2.8 ADVERUM BIOTECHNOLOGIES, INC.
- 13.2.9 REMEGEN
- 13.2.10 SPARINGVISION
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
